264 related articles for article (PubMed ID: 27317300)
1. Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease.
Concannon RM; Okine BN; Finn DP; Dowd E
Exp Neurol; 2016 Sep; 283(Pt A):204-12. PubMed ID: 27317300
[TBL] [Abstract][Full Text] [Related]
2. Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease.
Concannon RM; Okine BN; Finn DP; Dowd E
Exp Neurol; 2015 Jul; 269():133-41. PubMed ID: 25895887
[TBL] [Abstract][Full Text] [Related]
3. Time-course of striatal Toll-like receptor expression in neurotoxic, environmental and inflammatory rat models of Parkinson's disease.
McCabe K; Concannon RM; McKernan DP; Dowd E
J Neuroimmunol; 2017 Sep; 310():103-106. PubMed ID: 28778432
[TBL] [Abstract][Full Text] [Related]
4. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
[TBL] [Abstract][Full Text] [Related]
5. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats.
Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
Behav Brain Res; 2013 Apr; 243():6-15. PubMed ID: 23295396
[TBL] [Abstract][Full Text] [Related]
6. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.
Naughton C; O'Toole D; Kirik D; Dowd E
Behav Brain Res; 2017 Jan; 316():160-168. PubMed ID: 27585560
[TBL] [Abstract][Full Text] [Related]
7. Differential pattern of motor impairments in neurotoxic, environmental and inflammation-driven rat models of Parkinson's disease.
Naughton C; Moriarty N; Feehan J; O'Toole D; Dowd E
Behav Brain Res; 2016 Jan; 296():451-458. PubMed ID: 26393432
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection by valproic acid in an intrastriatal rotenone model of Parkinson's disease.
Carriere CH; Kang NH; Niles LP
Neuroscience; 2014 May; 267():114-21. PubMed ID: 24613722
[TBL] [Abstract][Full Text] [Related]
9. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB
Navarro G; Borroto-Escuela D; Angelats E; Etayo Í; Reyes-Resina I; Pulido-Salgado M; Rodríguez-Pérez AI; Canela EI; Saura J; Lanciego JL; Labandeira-García JL; Saura CA; Fuxe K; Franco R
Brain Behav Immun; 2018 Jan; 67():139-151. PubMed ID: 28843453
[TBL] [Abstract][Full Text] [Related]
10. GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease.
Hoban DB; Howard L; Dowd E
Neuroscience; 2015 Sep; 303():402-11. PubMed ID: 26166730
[TBL] [Abstract][Full Text] [Related]
11. Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain.
Torres E; Gutierrez-Lopez MD; Borcel E; Peraile I; Mayado A; O'Shea E; Colado MI
J Neurochem; 2010 Apr; 113(1):67-78. PubMed ID: 20067581
[TBL] [Abstract][Full Text] [Related]
12. Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of α-Synuclein in the Rat Brain.
Kelly R; Bemelmans AP; Joséphine C; Brouillet E; McKernan DP; Dowd E
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056822
[TBL] [Abstract][Full Text] [Related]
13. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic insights into the protective effect of paracetamol against rotenone-induced Parkinson's disease in rats: Possible role of endocannabinoid system modulation.
Labib AY; Ammar RM; El-Naga RN; El-Bahy AAZ; Tadros MG; Michel HE
Int Immunopharmacol; 2021 May; 94():107431. PubMed ID: 33578261
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease.
Javed H; Azimullah S; Haque ME; Ojha SK
Front Neurosci; 2016; 10():321. PubMed ID: 27531971
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial complex I inhibition depletes plasma testosterone in the rotenone model of Parkinson's disease.
Alam M; Schmidt WJ
Physiol Behav; 2004 Dec; 83(3):395-400. PubMed ID: 15581661
[TBL] [Abstract][Full Text] [Related]
17. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
Palomo-Garo C; Gómez-Gálvez Y; García C; Fernández-Ruiz J
Pharmacol Res; 2016 Aug; 110():181-192. PubMed ID: 27063942
[TBL] [Abstract][Full Text] [Related]
18. Role of L-thyroxin in counteracting rotenone induced neurotoxicity in rats.
Salama M; Helmy B; El-Gamal M; Reda A; Ellaithy A; Tantawy D; Mohamed M; El-Gamal A; Sheashaa H; Sobh M
Environ Toxicol Pharmacol; 2013 Mar; 35(2):270-7. PubMed ID: 23357603
[TBL] [Abstract][Full Text] [Related]
19. Protective role of apigenin on rotenone induced rat model of Parkinson's disease: Suppression of neuroinflammation and oxidative stress mediated apoptosis.
Anusha C; Sumathi T; Joseph LD
Chem Biol Interact; 2017 May; 269():67-79. PubMed ID: 28389404
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of a novel model of Parkinson's disease by intra-striatal infusion of the pesticide rotenone.
Mulcahy P; Walsh S; Paucard A; Rea K; Dowd E
Neuroscience; 2011 May; 181():234-42. PubMed ID: 21277943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
